r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

KT

Kevin Tang

Insider · 10% owner · BOLD

Kevin Tang files insider transactions with the SEC as a 10% owner of Boundless Bio (BOLD). We hold 30 disclosed purchases and sales filed since 13 February 2006, 24 of them in the last 90 days.

  • Files forBOLD
  • Disclosed buys and sells30 in all, 24 in the last 90 days
  • Last disclosure28 August 2026

Positions held

20 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 25 June 2026 — 26 August 202610% owner · Boundless Bio (BOLD)23 Form 4 lines · source: SEC Form 4
  • Filed 13 July 2026 — 17 July 202610% owner · Fulcrum Therapeutics (FULC)6 Form 4 lines · source: SEC Form 4
  • Filed 5 December 2024 — 2 June 2026Chief Executive Officer · Aurinia Pharmaceuticals (AUPH)30 Form 4 lines · source: SEC Form 4
  • Filed 21 February 2025 — 21 February 202510% owner · Singular Genomics Systems (OMIC)1 Form 4 line · source: SEC Form 4
  • Filed 11 May 2023 — 12 May 202310% owner · Tcr2 Therapeutics (TCRR)2 Form 4 lines · source: SEC Form 4
  • Filed 3 May 2023 — 3 May 2023Director and 10% owner · Jounce Therapeutics (JNCE)2 Form 4 lines · source: SEC Form 4
  • Filed 2 October 2014 — 22 August 2022Chief Financial Officer · La Jolla Pharmaceutical Co (LJPC)39 Form 4 lines · source: SEC Form 4
  • Filed 23 February 2018 — 23 December 2020Chief Executive Officer · Odonate Therapeutics (ODT)24 Form 4 lines · source: SEC Form 4
  • Filed 12 December 2014 — 7 January 2020Other role · Heron Therapeutics, Inc. /de/ (HRTX)30 Form 4 lines · source: SEC Form 4
  • Filed 25 April 2008 — 10 January 2014Director and 10% owner · Heron Therapeutics, Inc. /de/ (APPA)9 Form 4 lines · source: SEC Form 4
  • Filed 19 September 2013 — 20 September 201310% owner · Mirati Therapeutics (MRTX)2 Form 4 lines · source: SEC Form 4
  • Filed 19 December 2007 — 19 June 2012Director and 10% owner · Ardea Biosciences, Inc./DE (RDEA)33 Form 4 lines · source: SEC Form 4
  • Filed 17 February 2009 — 10 March 200910% owner · Penwest Pharmaceuticals Co (PPCO)5 Form 4 lines · source: SEC Form 4
  • Filed 9 August 2006 — 15 December 2008Director · Trimeris (TRMS)19 Form 4 lines · source: SEC Form 4
  • Filed 15 September 2008 — 13 October 200810% owner · Aradigm (ARDM)2 Form 4 lines · source: SEC Form 4
  • Filed 19 September 2008 — 25 September 200810% owner · Vanda Pharmaceuticals (VNDA)3 Form 4 lines · source: SEC Form 4
  • Filed 15 September 2008 — 24 September 200810% owner · Neose Technologies (NTEC)3 Form 4 lines · source: SEC Form 4
  • Filed 27 March 2008 — 14 May 200810% owner · Northstar Neuroscience (NSTR)11 Form 4 lines · source: SEC Form 4
  • Filed 23 October 2006 — 19 February 200810% owner · Tapestry Pharmaceuticals (TPPH)6 Form 4 lines · source: SEC Form 4
  • Filed 15 June 2007 — 15 June 2007Director and 10% owner · Ardea Biosciences, Inc./DE (ARDC)2 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.